A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Phase 1
103
about 3.5 years
18+
1 site in TX
What this study is about
Researchers are testing a treatment called BGC515 in adults with advanced solid tumors. The goal is to see if the treatment is safe and how it works in the body, as well as whether it shows any early signs of effectiveness. The trial will last for about 1282 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BGC515
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose-limiting toxicities (DLTs), Incidence of adverse events (AEs) and serious adverse events (SAEs)., Objective response rate (ORR), Progress-free survival(PFS)
Secondary: Half-life (t1/2)., Peak concentration (Cmax)., Time to peak concentration (Tmax).
Oncology